Recruiting

Anti-Reflux Endoscopic TX

Sponsor:

Midwest Veterans' Biomedical Research Foundation

Code:

NCT05570448

Conditions

Gastro Esophageal Reflux

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ARAT

Sham intervention (control)

Study Details

Brief summary:

This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months.

Patients must have a positive pH test and a negative manometry (no treatment) procedure.

Conditions

Gastro Esophageal Reflux

Study ID

NCT05570448

Start date

Feb 15, 2022

Status verified date

Feb, 2026

Completion date

Apr 1, 2027

Anticipated

Primary completion date

Feb 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Chronic GERD symptoms (at least 1 typical symptom of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for last 6 months
  • Objective evidence of reflux disease (positive ambulatory pH study.)

Exclusion Criteria:

  • Patients unable to or unwilling to participate or consent.
  • Age <18 years or >80 years.
  • Allergic or intolerant to PPI medications.
  • Large hiatal hernia > 3 cm and Hill grade IV.
  • Barrett's esophagus.
  • Esophageal stricture with any prior intervention.
  • Major motility disorder.
  • Eosinophilic esophagitis.
  • Gastroparesis documented by abnormal gastric emptying time.
  • Previous fundoplication, myotomy or LINX surgery.
  • Cirrhosis with esophageal and/or gastric varices.

Study Design

Enrollment

36 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Anti-reflux mucosal ablation (ARAT)

ablation in the gastric cardia using hybrid argon plasma coagulation

sham comparator: No treatment

no ablation

Interventions

ARAT

For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.

Sham intervention (control)

Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.

Primary outcome measure

  • Change in GERD health related quality of life (GERD-HRQL) score [ Time Frame: At 3, 6 and 12 months ]

Central Contacts and Locations

Central contacts

Locations

Kansas City VA Hospital

Recruiting

Kansas City, Missouri, United States, 64128

Contacts

Principal Investigator:

Prateek Sharma, MD

More Information

Sponsor

Midwest Veterans' Biomedical Research Foundation

Last update posted

Feb 27, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Midwest Veterans' Biomedical Research Foundation on 2026-02-27.